RxDoctor Payments Data

Vivian Carta Sanchez

Gerontology · West Palm Beach, FLNPI 1922201425

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 16 payments — averaging $70.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$357
  • Silk Road Medical, Inc.$217
  • Boston Scientific$149
  • AstraZeneca$135
  • Lilly USA, LLC$111
  • Astellas Pharma US Inc$94
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$1,02692%
  • Education$948%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,120 in reported general payments places this provider in the 65th percentile of 714 gerontology providers in Florida.

See all gerontology providers in Florida

Medicare billing

Part B allowed, 2024
$91,128
Medicare patients
251
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$94,424
MounjaroTirzepatide58$69,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$58,676
ProliaDenosumab29$49,133
EliquisApixaban54$45,090
MyrbetriqMirabegron38$30,978
XareltoRivaroxaban24$26,143
JardianceEmpagliflozin28$22,966
FarxigaDapagliflozin Propanediol29$22,191
RybelsusSemaglutide12$18,374
Tresiba Flextouch U-100Insulin Degludec31$11,374
GemtesaVibegron14$8,106
Tresiba Flextouch U-200Insulin Degludec12$7,097
Rosuvastatin Calcium268$3,848
SynthroidLevothyroxine Sodium40$3,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$13$112,79882 claims
Lilly USA, LLCMounjaro$111$69,15658 claims
GSKTrelegy Ellipta$357$58,67683 claims
Astellas Pharma US IncMyrbetriq$94$30,97838 claims
AstraZenecaFarxiga$135$22,19129 claims
AbbVieSynthroid$29$3,42740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 714 gerontology providers in Florida.

Other gerontology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →